Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of LY4395089 + mirikizumab versus mirikizumab alone in adults with moderately to severely active Crohn's disease
CTR20262036Phase 2Active
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of LY4395089, mirikizumab in Crohn's disease, sponsored by Eli Lilly and Company. Started Jul 2026; status: active.
02
Drugs
LY4395089mirikizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on CTR20262036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262036.